NCT07370363Not yet recruiting
Exercise Effects on Cardiometabolic Health and Sestrin-2 in Hypertensive Obese Women
Effects of Moderate-Intensity Continuous Exercise Versus Brisk Interval Exercise on Cardiometabolic Parameters and Sestrin-2 Levels in Hypertensive Obese Women: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 27 Jan 2026
Brief summary (registry, in English)
Obesity is a chronic and complex disease characterized by excessive fat accumulation that adversely affects health and quality of life. It is commonly accompanied by low-grade chronic systemic inflammation, which contributes to the development of insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular diseases. Hypertension is highly prevalent among individuals with obesity, and excess body weight is a major contributor to elevated blood pressure and related cardiometabolic risk. Regular aerobic exercise is a cornerstone of non-pharmacological management for both obesity and hypertension and has been shown to reduce chronic inflammation by downregulating pro-inflammatory pathways and upregulating anti-inflammatory mechanisms. Sestrin-2, a stress-responsive protein encoded by the SESN2 gene, has been proposed as an important regulator of metabolic homeostasis and inflammation through activation of the AMPK pathway and inhibition of NF-κB signaling. However, evidence regarding the effects of different exercise modalities on circulating Sestrin-2 levels in hypertensive obese individuals remains limited. This prospective, randomized controlled trial aims to compare the effects of two different aerobic exercise protocols on serum Sestrin-2 levels, inflammatory status, and cardiometabolic parameters in hypertensive obese women. Cardiopulmonary exercise testing will be used to comprehensively assess cardiorespiratory fitness and physiological responses to exercise. The results of this study are expected to contribute to a better understanding of exercise-induced anti-inflammatory mechanisms and to support the development of safe, effective, and applicable exercise prescriptions for hypertensive obese women.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- First submitted
- 4 Jan 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 1 May 2026
- Lead sponsor
- Havva Talay Çalış
- Diseases
- Obesity, High blood pressure
- NCT number
- NCT07370363
What you commit to
- Study type: Interventional
- Planned participants: 42
- From 1 Feb 2026 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chronic kidney disease or patients receiving dialysis
- Use of systemic corticosteroids or immunosuppressive medications
Other illness
- Neuromuscular disorders, uncontrolled psychiatric diseases, or cognitive impairment limiting exercise participation
- Congestive heart failure, unstable angina, or acute cardiac conditions including acute myocardial infarction, acute endocarditis, myocarditis, or pericarditis
- Presence of uncontrolled systemic diseases, including:
- Uncontrolled hypertension
- Uncontrolled diabetes mellitus
- Chronic liver failure
- Chronic obstructive pulmonary disease or asthma
- History or presence of malignancy
- Acute infection at the time of enrollment
- Acute peripheral vascular disease
Other
- Symptomatic severe aortic stenosis
- Acute pulmonary embolism or pulmonary infarction
- Inability to comply with the study protocol or lack of cooperation
- Refusal to participate in the study
Who the study is looking for
- Female participants aged between 30 and 65 years
- Body mass index between 30.0 and \<40.0 kg/m² (Class I and Class II obesity)
- Diagnosis of hypertension according to the 2018 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines
- Sedentary lifestyle, defined as total weekly exercise duration of less than 60 minutes
- Medically eligible for exercise participation, with approval from a Physical Medicine and Rehabilitation specialist and an Internal Medicine specialist
- Willingness to participate in the study and provision of written informed consent
Age in the registry: 30 years to 65 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kayseri City Hospital Coordinator of this site? Confirm its status | Kayseri | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.